Mod­er­na bol­sters glob­al hopes in Covid-19 vac­cines, but big ob­sta­cles re­main

5 years ago
Coronavirus

News brief­ing: Gilead, No­vo of­fer first glimpse at NASH cock­tail da­ta; Sean Bo­hen's can­cer biotech sets terms for ...

5 years ago
News Briefing

Retrophin no more: Shkre­li's lega­cy dis­ap­pears as for­mer com­pa­ny be­comes Tra­vere Ther­a­peu­tics

5 years ago
People
Pharma

Covid-19 roundup: In­ovio fi­nal­ly gets PhII rolling — but there's still a clin­i­cal hold; Low cost vac­cine en­ters ...

5 years ago
Coronavirus

One of biotech's flashiest star­tups is fi­nal­ly get­ting some com­pe­ti­tion from a pi­o­neer in a brand new field

5 years ago
Startups

Fa­heem Has­nain is go­ing back to run­ning a biotech start­up. And he has his work cut out for him

5 years ago
People
R&D

Sanofi grap­ples with re­jec­tion of po­ten­tial first-in-class or­phan drug, faults third-par­ty man­u­fac­tur­ing

5 years ago
FDA+

A phar­ma R&D chief jumps to a bud­ding new start­up fac­to­ry — and this time he’s found 'some­thing com­plete­ly ...

5 years ago
People
Startups

J&J taps in­to BAR­DA well a third time to speed up its PhI­II Covid-19 vac­cine tri­al

5 years ago
Coronavirus

Mod­er­na says its vac­cine is 94.5% ef­fec­tive at pre­vent­ing Covid-19, ap­pears to stop se­vere dis­ease

5 years ago
R&D
Coronavirus

Mer­ck­'s Keytru­da nets an­oth­er ap­proval, this time in triple neg­a­tive breast can­cer. Can it catch up to Tecen­triq?

5 years ago
FDA+

Cy­to­ki­net­ics cheers a PhI­II read­out for their heart drug de­vel­oped with Am­gen, but an­a­lysts and in­vestors aren't ...

5 years ago
R&D

Vac­cine czar Slaoui ex­pects Mod­er­na's first Covid-19 da­ta to come 'prob­a­bly next week,' plans for 20M im­mu­niza­tions ...

5 years ago
Coronavirus

Short­age of mon­keys slowed down Eli Lil­ly's Covid-19 an­ti­body part­ner. And it's a prob­lem for every­one

5 years ago
R&D
China

News brief­ing: Seer heads to Nas­daq with $150M IPO; IN8bio post­pones pub­lic de­but amid record year on Wall Street

5 years ago
News Briefing

An ex-Vant fur­ther im­mers­es it­self in a new um­brel­la, cash­ing out in a $584M M&A deal with Sum­it­o­mo Dainip­pon ...

5 years ago
Deals

Bio­Marin CEO Bi­en­aimé beats a re­treat from Eu­rope, yank­ing their ap­pli­ca­tion for he­mo­phil­ia A gene ther­a­py

5 years ago
R&D
FDA+

As the cur­tain clos­es on the Trump pres­i­den­cy, biotech wres­tles with its fu­ture in a di­vid­ed Amer­i­ca

5 years ago
People
In Focus

CDER's Janet Wood­cock: Phar­ma, reg­u­la­tors have lessons to learn from Covid-19

5 years ago
FDA+
Coronavirus

Af­ter No­vo Nordisk's ac­qui­si­tion of Cor­vidia, Ram Ai­yar takes the helm at Ko­r­ro Bio; Sil­ver­back gets a new CFO to go ...

5 years ago
Peer Review

No thanks: Roche backs out of EGFR-re­lat­ed pro­tein de­graders in re­vised deal with C4

5 years ago
Deals

Covid-19 roundup: J&J part­ners with Unit­ed­Health to hit the gas on vac­cine tri­al en­roll­ment; BioN­Tech CEO Ugur Sahin ...

5 years ago
Coronavirus

In­ter­fer­on be­ta-1a can­di­date for COPD ad­vances to PhI­II to test its po­ten­tial against Covid-19

5 years ago
R&D
Coronavirus

Dou­bling down on Sanofi's French roots, Paul Hud­son in­fus­es €50M in­to Jeito Cap­i­tal to boost home­grown biotechs

5 years ago
Financing
First page Previous page 777778779780781782783 Next page Last page
A service from the Financial Times